Condition
Acute Demyelinating Syndrome
Total Trials
1
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
3 treatments under study, led by Standard Of Care
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
100%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 3 (1)
Trial Status
Recruiting1
Clinical Trials (1)
Research Network
Common Treatments
- Standard Of Care1
- Immediate Azathioprine 1st Attack1
- Immediate Rituximab 1st Attack1
Active Sponsors
- Institut National de la Santé Et de la Recherche Médicale, France1
- Assistance Publique - Hôpitaux de Paris1
- Assistance Publique Hopitaux De Paris1
Related Conditions
- Myelin Oligodendrocyte Glycoprotein Antibodyassociated Disease1
- Myelin Oligodendrocytes Glycoprotein Antibody Associated Diseasesmogad1